An interventional study of Optimune and Care-As-Usual in Breast Cancer, sponsored by Technical University of Dortmund. Completed at 2 sites in Germany. Open to female participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-10-08.
Sponsored by Technical University of Dortmund · Not applicable, Interventional, and Treatment
The trial aims to evaluate the effectiveness of a novel web-based intervention (Optimune), which was designed to introduce relevant cognitive-behavioral therapy (CBT) techniques to women with breast cancer who are past the active eradication phase. The present study will test the hypothesis that Optimune has an impact on lifestyle parameters and psychometric outcomes. Therefore, 360 woman with breast cancer will be recruited and randomized to two groups: (1) a control group, in which they may engage with any treatment (Care-as-Usual, CAU) and receive access to Optimune after a delay of 3 months (i.e., CAU/wait list control group), or (2) to a treatment group that immediately receives 12-month access to Optimune and may also use CAU. The primary outcome measure is the effect on quality of life, physical activity and diet three month post-baseline.
Depression and fatigue is common in breast cancer survivors and its presence is associated with personal suffering, increased inflammatory activity, and worse prognosis. While in the phase of acute treatment many women receive short-term psychological support to better cope with the situation, this is not standard of care in the years following. Web-based psychological interventions are easily accessible and preliminary evidence suggests that such interventions can be effective. However, no trial has yet examined whether a CBT-based internet intervention designed to meet the needs of breast cancer survivors can achieve effects on lifestyle parameters and psychometric outcomes, when offered as adjunct to care as usual.
In this study, the investigators will investigate treatment effects of the novel web-based program Optimune when added to treatment as usual. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep and stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). The delivery and training of content is continuously individualized to match users' preferences and needs, based on responses within the program. The intervention is delivered via the internet and protected by individually assigned passwords. The program can be accessed for 365 days after registration.
This randomized controlled trial will include 360 women with breast cancer who are past the active eradication phase. Participants will be recruited from various settings, including web-based advertisement and internet forums/groups. Participants will be randomly assigned to either (1) a control group, in which they receive care as usual (CAU) and are given access to the web-based intervention (Optimune) after a delay of 3 months (i.e., CAU/wait list control group), or (2) a treatment group that may also use CAU and in addition immediately receives 12-month access to the web-based intervention (Optimune). Measurements are collected at pre-treatment (T0) three months (T1) and six months (T2).
Eligible are women who
Optimune is an web-based psychological intervention for women with breast cancer. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep, stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). Content is continuously adapted to users' concerns and needs. It contains interactive dialogues that can be accessed via computer or smart-phone, illustrations, audio files and motivating text messages. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
Behavioral: Optimune
As in the experimental arm, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Optimune six months post-baseline (i.e., wait list with respect to Optimune access).
Other: Care-As-Usual
Optimune is a web-based psychological intervention developed for women with breast cancer.
Participants are free to continue to engage with any treatment they require (i.e., CAU).
Determination of Quality of Life using the WHOQOL-BREF
Quality of Life will be measured using the World Health Organization Quality of Life Questionnaire (WHOQOL-BREF), which is a shorter version of the original instrument. Scale Range: 26 to 130. The WHOQOL-BREF is a 26-item, 5-point rating scale. It measures the following broad domains: physical health, psychological health, social relationships, and environment. Response options range from 1, indicating "very dissatisfied" to 5, indicating "very satisfied" and relate to the last two weeks. Higher scores on the WHOQOL-BREF correspond to higher self-reported levels of quality of life.
Time frame: Change from baseline to 3 months (also assessed at 6 months post-baseline)
Determination of Physical Activity using the International Physical Activity Questionnaire
Physical Activity will be measured using the short version of the International Physical Activity Questionnaire (IPAQ - short). The short version of the IPAQ is a 7-item questionnaire that assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives. Open-ended questions surrounding individuals' last 7-day recall of physical activity are considered to estimate total physical activity min/week and time spent sitting. Interpretation: Three levels (categories) of physical activity are proposed: low, moderate and high.
Time frame: Change from baseline to 3 months (also assessed at 6 months post-baseline)
Determination of Diet Quality using the Food Quality Questionnaire
Diet Quality will be measured using the Food Quality Questionnaire (FQQ). Scale Range: 0 to 39. The FQQ is a 10-item, 5-point rating scale. The FQQ is a short food frequency questionnaire, which includes 10 food items on a 5-point rating scale. It focuses on fruit, vegetables, high-sugar foods, processed food, meat and drinks. The aim of the tool is to measure diet quality. Response options range from 0, indicating "daily" to 3" indicating, "once or never". Interpretation: A global diet quality score can be obtained by averaging all the items on the FQQ.
Time frame: Change from baseline to 3 months (also assessed at 6 months post-baseline)
Determination of cancer-related fatigue using the Brief Fatigue Inventory Questionnaire
Fatigue will be measured using the Brief Fatigue Inventory Questionnaire (BFI-9) questionnaire. Scale Range: 0 to 90. The BFI is a 9-item, 11-point rating scale. The first three questions measure fatigue severity from 0, indicating "no fatigue," to 10, indicating "as bad as you can imagine," at current, usual, and worst levels. The following six questions assess fatigue interference with daily activities. Response options range from 0, indicating "does not interfere," to 10, indicating, "completely interferes." Interpretation: A global fatigue score can be obtained by averaging all the items on the BFI. Higher scores on the BFI correspond to greater self-reported levels of fatigue
Time frame: Change from baseline to 3 months (also assessed at 6 months post-baseline)
Determination of cancer-related emotional stress
Cancer-related emotional stress will be measured using the standardized IES-R (Impact of Event Scale) Questionnaire. Scale Range: 0 to 88 The IES-R is a 22-item self-report measure that assesses subjective distress caused by traumatic events. Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The IES-R yields a total score (ranging from 0 to 88) and subscale scores can also be calculated for the Intrusion, Avoidance, and Hyperarousal subscales. Interpretation: Higher scores correspond to greater self-reported levels of post-traumatic stress.
Time frame: Change from baseline to 3 months (also assessed at 6, 9 and 12 months post-baseline)
Determination of depression
Depression will be measured using the standardized PHQ-9 (Patient Health Questionnaire). Scale Range: 0 to 27 The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. PHQ-9 scores of 5, 10, 15, and 20 represents mild, moderate, moderately severe and severe depression. Interpretation: Higher scores correspond to greater self-reported levels of depression.
Time frame: Change from baseline to 3 months (also assessed at 6 months post-baseline)
Determination of anxiety
Anxiety will be measured using the standardized GAD-7 (Generalized Anxiety Disorder) questionnaire. Scale Range: 0 to 21 The GAD-7 is an instrument for screening, diagnosing, monitoring and measuring the severity of anxiety. GAD-7 scores of 5, 10, and 15 represents mild, moderate, and severe anxiety. Interpretation: Higher scores correspond to greater self-reported levels of anxiety.
Time frame: Change from baseline to 3 months (also assessed at 6 months post-baseline)
Determination of fear of progression
Fear of progression will be measured using the standardized PA-F12 (Fear of progression) questionnaire. Scale Range: 12 - 60 The PAF-12 items are scored on a five-point Likert Scale ranging from 1 ('never') to 5 ('very often'), higher values indicating higher levels of anxiety. Interpretation: Higher scores correspond to greater self-reported levels of fear of progression.
Time frame: Change from baseline to 3 months (also assessed at 6 months post-baseline)
Determination of insomnia
Insomnia will be measured using the standardized - ISI (Insomnia Severity Index), Scale Range: 0 - 28, higher values indicating increasing severity of insomnia
Time frame: Change from baseline to 3 months (also assessed at 6 months post-baseline)
Determination of usefulness of the program
Usefulness of the program will be measured by a questionnaire
Time frame: Assessed at 3 and 6 months
Determination of Negative Effects
Negative Effects will be measured using the standardized INEP (Inventory for the Assessment of Negative Effects of Psychotherapy) questionnaire.
Time frame: Assessed at 3 and 6 months
Determination of recurrence of breast cancer (local relapse or remote metastasis)
Recurrence of breast cancer (local relapse or remote metastasis) will be determined by a questionnaire
Time frame: Change from baseline to 3 months (also assessed at 6 months post-baseline)
Frequency of common cold or virus flu
Frequency of common cold or virus flu will be determined by a questionnaire
Time frame: Change from baseline to 3 months (also assessed at 6 months post-baseline)
Frequency of unscheduled medical encounters
Frequency of unscheduled medical encounters will be determined by a questionnaire
Time frame: Change from baseline to 3 months (also assessed at 6 months post-baseline)
Body Mass Index
Height and weight will be determined by a questionnaire
Time frame: Change from baseline to 3 months (also assessed at 6 months post-baseline)
Psychotherapy
A questionnaire will determine if a psychotherapy has started during the trial
Time frame: Change from baseline to 3 months (also assessed at 6 months post-baseline)
Plan to share: Yes — Anonymized individual participant data shall be made available upon request for projects such as meta-analyses after completion of the study
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Technical University of Dortmund